ENKAM's Protein Mimetic Technology Platform (PMTP) has primarily been applied to novel and known targets within two therapeutic areas: CNS disorders and oncology


ENKAM Pharmaceuticals A/S

_________________________________________________________________

ENKAM Pharmaceuticals A/S is a biopharmaceutical development company focused on cancer and CNS disorders.

 

ENKAM’s Protein Mimetic Technology Platform (PMTP™) allows the creation of active peptides which mimic specific functions of larger proteins.

 

The Company has several compounds in pre-clinical and clinical development for Alzheimer’s Disease, Huntington’s Disease, and breast and prostate cancer. The Company has a rich inventory of active peptides and the ability to quickly create new peptides which segregate specific activities of multifunctional proteins.

  • ENKAM Pharmaceuticals A/S
  • Fruebjergvej 3, Box 58
  • 2100 Copenhagen Ø
  • Denmark
  • Phone: +4539179715
  • Fax: +4539179714